Hospira Announces Important Safety Information Regarding Carpuject Syringe System and the Potential For Overfill

Monday May 21st 2012 12:10:00 PM

Hospira Convenes Its 2012 Annual Meeting of Shareholders

Wednesday May 9th 2012 01:24:00 PM

LAKE FOREST, Ill., May 9, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today held its 2012 Annual Meeting of Shareholders in Arlington, Va.  The agenda included votes on five items. During the annual meeting, shareholders: elected the following directors: Barbara L. Bowles, Roger W. Hale and John C. Staley, all Class II directors whose terms expire in 2015; and William G. Dempsey, a Class III director whose term expires in 2013; approved two amendments to Hospira's restated certificate of incorporation to permit shareholders to call special meetings in accordance with the company's bylaws and to phas...

Hospira to Present at Upcoming Investor Conferences

Tuesday May 8th 2012 01:01:00 PM

LAKE FOREST, Ill., May 8, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that the company will present at the following upcoming conferences: * Sanford C. Bernstein's Twenty-Eighth Annual Strategic Decisions Conference 2012 May 31, 2012 (Thursday) - New York 2:00 p.m. Eastern time * Goldman Sachs 33rd Annual Global Healthcare Conference June 6, 2012 (Wednesday) - Los Angeles 10:40 a.m. Pacific time The presentations will be available to all interested parties through a live audiocast accessible via the investor relations section of Hospira's ...

Hospira Reports First-Quarter 2012 Results

Tuesday May 1st 2012 07:31:00 AM

-- Maintains sales and adjusted* earnings projections for 2012 -- LAKE FOREST, Ill., May 1, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today reported results for the first quarter ended March 31, 2012. Net sales for the quarter were $966 million and adjusted* diluted earnings per share were $0.47. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.) "Hospira delivered first-quarter results in line with our expectations, which reflects a difficult year-over-year comparison and the impact of our quality improvement initiatives," said F. Micha...

Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

Thursday April 26th 2012 01:02:00 PM

LAKE FOREST, Ill., April 26, 2012 /PRNewswire via COMTEX/ --Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that the company will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Wednesday, May 16, 2012, in Las Vegas. The presentation is scheduled to begin at 8:40 a.m. Pacific time on Wednesday, May 16, 2012. It will be available to all interested parties through a live audiocast accessible via the investor relations section of Hospira's website at www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. A replay of...

Hospira Infusion Pumps Ranked Top Devices in New KLAS Smart Pumps 2012 Report

Thursday April 12th 2012 10:47:00 AM

Symbiq(TM) and LifeCare PCA(TM) infusion pumps receive top category marks in hospital customer survey -- LAKE FOREST, Ill., April 12, 2012 /PRNewswire via COMTEX/ --Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced its Symbiq(TM) and LifeCare(TM) PCA infusion pumps have been ranked as the top devices in their categories in the KLAS report, Smart Pumps 2012: Wireless Technology and EMR Integration Report. Hospira was also recognized as the "early leader" in electronic medical record (EMR) integration with infusion pumps. The rankings are based on data from customer surveys of North American hospital and clinic executives...

Hospira Names John B. Elliot Senior Vice President of Operations

Wednesday April 11th 2012 04:00:00 PM

-- Elliot Brings Extensive Industry Experience and Complements Recently Strengthened Operations Organization -- LAKE FOREST, Ill., April 11, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that John B. Elliot has been named senior vice president, Operations, effective April 16. In this role, Mr. Elliot will have overall responsibility for Hospira's global operations organization and serve as a member of Hospira's senior leadership team. He will report directly to F. Michael Ball, chief executive officer. "John is a seasoned global leader with more than 35 years of broad manufacturing experience ...

Hospira to Host Conference Call for First-quarter 2012 Results

Monday April 2nd 2012 02:46:00 PM

LAKE FOREST, Ill., April 2, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, will host a conference call to discuss its first-quarter 2012 results on Tuesday, May 1, 2012 at 8 a.m. Central time.  The company will release its first-quarter results earlier that morning, before the U.S. stock market open and the conference call. A live webcast of the conference call and related material will be available on Hospira's website at www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on the Hospira website for ...

Hospira's TheraDoc(TM) Clinical Surveillance System to Support Infection Prevention and Patient Safety Efforts at CHRISTUS Health

Friday March 9th 2012 02:51:00 PM

During National Patient Safety Week, multi-hospital system reinforces commitment to high-quality patient care by ensuring that relevant patient data are available enterprise wide -- LAKE FOREST, Ill., March 9, 2012 /PRNewswire via COMTEX/ --Hospira (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that CHRISTUS Health, one of the country's 10 largest Catholic healthcare systems, has selected Hospira's TheraDoc(TM) clinical surveillance system to support its patient safety and infection prevention efforts across 23 hospitals in Arkansas, Louisiana and Texas. CHRISTUS hospitals will use the Clinical Intelligence(TM) Platform -- whic...

Hospira Receives FDA Clearance for Symbiq(TM) 3.13 Infusion Pump

Thursday March 8th 2012 06:44:56 PM

One of the first general infusion pumps to receive clearance under new infusion pump 510(k) regulatory guidance -- LAKE FOREST, Ill., March 8, 2012 /PRNewswire via COMTEX/ --Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today that the company has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Symbiq(TM) 3.13 infusion device, the enhanced version of the company's advanced infusion system platform. The clearance is one of the first to be granted through the new draft FDA regulatory guidance for 510(k) infusion pump submissions. Hospira is planning to start working with current custome...